HDA Media And Political Bulletin – 25 April 2016

April 2016 NCSO/Price Concessions update

22 April 2016, PSNC


The Department of Health granted the following price concessions for April 2016:

The price concession only applies to the month that it is granted.


Drug Pack size Price concession
Bumetanide 1mg tablets 28 £2.05
Celiprolol 400mg tablets 28 £39.65
Cimetidine 400mg tablets 60 £19.99
Desmopressin 10micrograms/dose nasal spray (new) 60 dose £24.00
Flecainide 50mg tablets 60 £7.50
Flecainide 100mg tablets 60 £6.83
Fludrocortisone 100mcg tablets (new) 100 £96.00
Lamotrigine 5mg dispersible tablets sugar free 28 £7.50
Mefenamic acid 500mg tablets 28 £10.25
Nitrofurantoin 100mg tablets (new) 28 £12.50
Nitrofurantoin 50mg tablets (new) 28 £11.50
Pioglitazone 15mg tablets 28 £19.20
Pioglitazone 30mg tablets 28 £24.32

Please note that PSNC cannot provide details of generic products that are suspected of being affected by generic supply problems unless and until the Department of Health grants a concession. No additional endorsements are required for price concessions.

If you have problems obtaining a Part VIII product or problems obtaining the product at the set Drug Tariff price, please report the issue to PSNC using the online feedback form on the PSNC Website.

If you have been able to source the product, please provide full details of the supplier and price paid. PSNC will investigate the extent of the problem and if appropriate discuss the issue with the Department of Health.

Any further concessions will be posted here on the website.


NICE publishes CD guidance

25 April 2016, Dispensing Doctor, Alisa Colquhoun


NICE has published new guidance on the safe use and management of controlled drugs. The guidance incudes advice such as prescribing no more than 30 days’ worth of a CD.



Parliamentary Coverage


There is no Parliamentary Coverage today.


Full Coverage

NICE publishes CD guidance

25 April 2016, Dispensing Doctor, Alisa Colquhoun


Guidance on the safe use and management of controlled drugs has been published by NICE.

The new guidance contains information on the following areas:

·         Developing and establishing systems and processes for organisations

·         Record keeping

·         Risk assessment

·         Processes for reporting controlled drug‑related incidents

·         Prescribing controlled drugs

·         Obtaining and supplying controlled drugs

·         Administering controlled drugs

·         Handling controlled drugs

·         Monitoring the use of controlled drugs

The guidance includes advice such as prescribe no more than 30 days’ worth of a CD. If a larger quantity is prescribed, the reasons for this should be documented in the person’s care record. A seven year review of medicines-related safety incidents concerning controlled drugs in England and Wales concludes that five commonly used controlled drugs were responsible for 113 incidents (88.4%) leading to serious harm (death and severe harm) with overdose accounting for 89 (69.5%) of the 128 incidents of serious harm.

A link to the NICE CD guidance has been placed in our library of controlled drugs resources.

HDA Media And Political Bulletin – 25 April 2016

From Factory to Pharmacy

As part of our mission to build awareness, understanding and appreciation of the vital importance of the healthcare distribution sector, we developed an infographic explaining the availability of medicines. It identifies the factors that can impact drug supply, as well as the measures that HDA members undertake day in, day out to help mitigate the risks of patients not receiving their medicines.

See the Infographic

Apply to become a Member

Membership of the HDA guarantees your organisation:

  • Access to leading policy and industry forums of debate and discussion
  • Invitations to a range of networking industry events organised through the year, including an Annual Conference and a Business Day
  • Representation on HDA working parties, including the Members’ Liaison Group
  • A daily Political and Media Bulletin and HDA Newsletters
  • Access to HDA policy documents and all sections of the HDA website
  • Branding and marketing opportunities
Apply Now

Already a Member?